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Abstract
Objective: Glutathione-S-transferases (GSTs) play an important role in tobacco smoke detoxification, interestingly
approximately 50% of individuals in most human populations lack the gene GSTM1 due to copy number variation (CNV). We
aimed to investigate GSTM1 CNV in Rheumatoid Arthritis (RA) in relation to smoking and HLA-DRB1 shared epitope; the two
best known risk factors for RA and in addition, to perform subanalyses in patients where relations between variations in
GSTM1 and RA have previously been described.
Methods: qPCR was performed using TaqMan Copy Number assays (Applied Biosystems) for 2426 incident RA cases and
1257 controls from the Swedish EIRA. Odds ratio (OR) together with 95% confidence intervals (CI) was calculated and used
as a measure of the relative risk of developing RA.
Results: No association between RA and GSTM1 CNV was observed when analyzing whole EIRA. However, $1 copy of
GSTM1 appears to be a significant risk factor for autoantibody positive RA in non-smoking females $60 years (OR: 2.00 95%
CI: 1.07–3.74), a population where such relationships have previously been described. Our data further suggest a protective
effect of GSTM1 in ACPA-negative smoking men (OR: 0.56 95% CI: 0.35–0.90).
Conclusion: We assessed the exact number of GSTM1 gene copies in relation to development and severity of RA. Our data
provide support for the notion that variations in copy numbers of GSTM1 may influence risk in certain subsets of RA, but do
not support a role for GSTM1 CNV as a factor that more generally modifies the influence of smoking on RA.
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Introduction
Rheumatoid arthritis (RA) is characterized by chronic inflam-
mation of synovial joints, resulting in progressive destruction of
cartilage and bone. Increasing evidence exist that genes and
environment interact in the development of the disease, and also
that two major subsets of RA exists defined by presence/absence
of antibodies to citrullinated protein antigens (ACPAs) [1]. In
particular, a smoking history together with the shared epitope
alleles (SE) of the HLA-DRB1 locus in the major histocompatibility
complex have repeatedly been found to strongly increase the risk
of developing RA, in ACPA-positive RA [2,3,4,5,6,7].
A central feature of RA is inflammation with the resulting
reactive oxygen species (ROS), which causes oxidation of
macromolecules giving rise to a variety of cytotoxic products.
ROS are produced by phagocytes in the synovial fluid and pannus
and by synovial endothelial cells during hypoxia-reperfusion
events. This means that variations in host effectiveness in
detoxification of products of ROS activity might be important
and there is growing evidence that ROS and their by-products
may play a direct role in the development of RA [8,9]. An
alternative view on oxidative mechanisms was developed when up-
regulation of NcfI in a rat model for arthritis was shown to be
protective [10]. These data indicate that genetic differences in
oxidative events may modulate the risk and/or severity of RA, and
that several mechanisms may be involved, some even working in
opposite directions. Since genetic polymorphisms of enzymes such
as glutathione S-transferases (GSTs) have been shown to have an
important role in detoxifying foreign substances from tobacco
smoke, influencing susceptibility to both lung and colon cancer
[11,12] it is tempting to speculate that such polymorphisms may
be of importance also for the development of RA, and that such
influences may be very complex [13].
Glutathione S-transferase M1 (GSTM1) a member of the GST m
class has been localized to human chromosome 1p13.3 and is
polymorphic in humans. Approximately 50% of individuals in
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activity of GSTM1 [14,15]. The deletion of the GSTM1 gene seems
to be caused by an unequal crossing over event between sequences
about 5 kb downstream from GSTM2 and GSTM1, which results
in the deletion of the entire GSTM1 gene [14]. Mammalian cells
constitutively express a number of detoxifying enzymes such as the
GST family. The GSTs, which are a superfamily of polymorphic
enzymes, play an important role in detoxification by catalyzing the
conjugation of many hydrophobic and electrophilic compounds
with reduced glutathione [8]. Protection against a broad range of
compounds including carcinogens, pesticides, antitumor agents
and environmental pollutants has been suggested to be mediated
in part by GSTs (OMIM 138350).
The GSTM1 copy number variation (CNV) is in a sense unique
and provides us with ‘‘natural knockouts’’ for this gene in human
population. It has been difficult however to detect the exact
number of gene copies and to discriminate the common state with
one copy from two copies. The absolute majority of previous
studies of GSTM1 genetics were able only to detect ‘‘null’’ allele
against ‘‘positive’’ and there are still no studies published which
have addressed susceptibility to RA in relation to the exact
number of copies of GSTM1.
Mattey et al., demonstrated in 1999 [16], that GSTM1 null RA
patients had more severe radiological progression (higher Larsen
score) independent of the effect of the HLA-DRB1 associated
shared epitope (SE). The same group later demonstrated that
smoking was specifically tightly associated with severe RA in
individuals who carried the GSTM1-null polymorphism [17].
Criswell et al. [18] described in 2006 the development of RA
among older Caucasian women and found a positive association
between GSTM1-null genotype and risk of disease. All these studies
were performed in relatively small cohorts (Mattey et al. [16], 164
patients; Mattey et al., [17], 277 patients and 577 controls,
Criswell et al. [18], 115 patients and 466 controls). In two other
studies (Yun BR et al., [8]; Morinobu S et al, [19]) with 258 RA
patients from Korea and 108 RA patients from Japan, risk of RA
development was also suggested to be higher in individuals lacking
the GSTM1 gene. However, recently Keenan et al. [20] published
a study using Nurses’ Health Study (549 RA patients and controls)
where no association was observed between presence/absence of
GSTM1. Hence, the data have so far been ambiguous.
In the present study, we aimed to investigate whether there is
any association between GSTM1 CNV and development as well as
severity of RA in a larger case-control study consisting of all
together 3682 individuals, including 2426 RA patients, using a
quantitative identification of the number of gene copies. We also
analyzed the impact of GSTM1 in RA in both the ACPA-positive
and ACPA-negative subsets of the disease separately.
Results
GSTM1 CNV as a risk factor for RA
The GSTM1 CNV frequencies in cases were 53.7% for 0 copies,
38.3% for 1 copy, 7.8% for 2 copies and 0.13% for 3 copies and in
controls 51.8% for 0 copies, 40.1% for 1 copy, 7.9% for 2 copies
and 0.08% for 3 copies. These frequencies are in line with what
has been published previously concerning Caucasian populations
[21,22]. Our genotyping quality control demonstrated 100%
match between commercial assay and our in-house PCR and the
distribution of genotypes was in Hardy-Weinberg equilibrium.
We performed analysis using the EIRA study for association
between GSTM1 CNV and RA risk. Overall, no significant
association was detected with development of RA, neither alone
(OR: 0.93 95% CI: 0.81–1.06) or after stratification by smoking
status (ORever smoker: 0.92 95% CI: 0.76–1.11) (ORnever smoker: 0.93
95% CI: 0.72–1.21) or by the SE alleles (ORno SE: 0.93 95% CI:
0.74–1.16) (ORyes SE: 0.91 95% CI: 0.76–1.09) (Table 1). We also
compared individuals with no copies of GSTM1 with individuals
with $2 copies and found similar results; GSTM1 CNV and
development of RA OR: 0.95 95% CI: 0.74–1.24, smoking
(ORever smoker: 0.94 95% CI: 0.66–1.36) (ORnever smoker: 1.02 95%
CI: 0.64–1.65) and SE (ORno SE: 1.06 95% CI: 0.68–1.65)
(ORyes SE: 0.84 95% CI: 0.60–1.17).
In addition to these data on GSTM1, our study confirms the
previously known risk factors for ACPA-positive RA, HLA-DRB1
SE alleles (OR: 3.73 95% CI: 2.83–4.92) and smoking (OR: 1.74
95% CI: 1.35–2.25) and also their combination (OR: 8.00 95%
CI: 4.96–12.89). Presence of GSTM1 did not significantly influence
this combined effect (among GSTM1 positive, OR: 7.46 95% CI:
4.61–12.06) (Table 2).
GSTM1 CNV in relation to RA severity
We performed analysis in our study to address to what degree
GSTM1 CNV associates with baseline disease activity (DAS28) and
with erosions at baseline, 1 and 2 years after disease onset. We
found no differences in DAS28 between individuals carrying 0, 1,
2 or 3 copies of GSTM1 (p=0.82) (Table 3). When studying X-ray
data we observed that Larsen score at baseline in female ever
smokers moderately associated to the gene copy number of
GSTM1 (p=0.04) (Table 4). The influence from GSTM1 was
significant when analyzing presence of the gene vs. absence
(p=0.006) but did not remain significant when analyzing $2 vs. 0
copies (non-corrected p=0.04). No association with GSTM1 CNV
was observed, however, when analyzing erosions in RA patients 1
or 2 years after disease onset.
GSTM1 CNV and RA risk in relation to age of onset of
disease
To test a hypothesis about an effect of GSTM1 in the
development of RA in older women, which was previously
suggested by Criswell et al. [18], we restricted our analyses to
ACPA-positive RA among women $60 years (mean age 64 years).
In our study we found an insignificant trend towards an
association between presence of GSTM1 and risk of ACPA
positive RA in these subjects (OR: 1.37 95% CI: 0.96–1.93)
(Table 4). When subdividing the subjects according to smoking
status, we found that presence of GSTM1 is significantly associated
with risk for ACPA-positive RA among never smoking women
$60 years old (OR: 2.00 95% CI: 1.07–3.74) and we also found a
trend for association between presence of GSTM1 and ACPA
positive RA among SE-negatives (OR: 2.02 95% CI: 0.98–4.16)
(Table 5). We noticed a similar, non-significant trend between
presence of GSTM1 and ACPA positive RA when analyzing never
smokers, not carrying SE (OR: 3.32 95% CI: 0.86–12.77).
Additionally, when stratifying for ACPA-status and gender we
saw a protective effect from the presence of GSTM1 in ACPA-
negative male smokers (OR: 0.56 95% CI: 0.35–0.90) (Table 4).
However, these latter results should be interpreted with caution
due to rather small groups and may well reflect chance effect.
Discussion
The major finding in our study is the identification of complex
associations between GSTM1 CNV and risk- and severity of RA.
Presence of GSTM1 was associated with an increased risk of
ACPA-positive RA among non-smoking older women, while
presence of GSTM1 was associated with a decreased risk of ACPA-
negative RA among male smokers. No association with disease, in
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when analyzing the whole study population. Notably, we did not
find any direct impact of GSTM1 CNV on the associations
between RA and the strongest risk factors for this disease, i.e. HLA
SE alleles and smoking. Instead our results suggest that variations
in copy numbers of GSTM1 may influence the risk for RA in ways
that are largely independent of smoking and HLA-DR SE genes.
Based on the EIRA study design, the group of patients who are
female, non-smokers and do not carry HLA-DR SE alleles are,
constitute only approximately 4% of the total RA population, and
it thus seems that GSTM1 CNV does not play a substantial role for
the majority of RA patients.
The absence of GSTM1 was previously found to be a risk factor
for RA and a factor contributing to disease severity [16,17]. Thus,
our new findings do not confirm some of the previous studies in
relation to possible effect of GSTM1 CNV. There are several
possible reasons for this lack of confirmation. First, our findings
may be a result from a type II error. We find this unlikely however,
since the power to detect an odds ratio in the order of 1.5 is
relatively high in our study. In contrast, all previous studies were
based on lower number of cases and are likely underpowered and
may thus represent results of type I errors. Second, the difference
from previous studies on GSTM1 in RA may be due to
dissimilarity between the study populations. EIRA is a population
based case-control study where controls have been randomly
selected and matched to the cases on sex, age and residential area
minimizing the potential for selection bias and population
stratification. Since most mentioned previously published studies
were cross sectional with long lasting RA (median 11 years [16],
,5 years [23], 7 years [19]) and our study was preformed in
Table 1. Frequency of GSTM1 CNV in EIRA by ACPA status and different subgroups according to smoking and HLA-DRB1 status.
GSTM1 – RA overall
GSTM1 Sex Ca/co OR 95% CI
No All 1282/479 1,00 -
Any All 1104/601 0,93 0.81–1.06
No Women 908/465 1,00 -
Any Women 792/425 0,95 0.81–1.12
No Men 374/182 1,00 -
Any Men 312/176 0,86 0.67–1.11
GSTM1 – ACPA-positive RA GSTM1 – ACPA-negative RA
GSTM1 Sex Ca/co OR 95% CI Ca/co OR 95% CI
No All 670/639 1,00 - 407/639 1,00 -
Any All 581/590 0,94 0.80–1.10 348/590 0,93 0.77–1.11
No Women 474/457 1,00 - 279/457 1,00 -
Any Women 412/419 0,95 0.79–1.14 260/419 1,02 0.82–1.26
No Men 196/182 1,00 - 128/182 1,00 -
Any Men 169/171 0,92 0.69–1.23 182/171 0,73 0.52–1.03
GSTM1 –RA among ever smokers GSTM1 –RA among never smokers
GSTM1 Sex Ca/co OR 95% CI Ca/co OR 95% CI
No All 600/330 1,00 - 295/215 1,00 -
Any All 530/318 0,92 0.76–1.11 259/202 0,93 0.72–1.21
No Women 412/232 1,00 - 228/161 1,00 -
Any Women 375/217 0,97 0.77–1.23 204/162 0,89 0.67–1.19
No Men 188/98 1,00 - 67/54 1,00 -
Any Men 155/101 0,80 0.56–1.14 55/40 1,11 0.64–1.91
GSTM1 –RA among SE-positives GSTM1 –RA among SE-negatives
GSTM1 Sex Ca/co OR 95% CI Ca/co OR 95% CI
No All 950/325 1,00 - 328/299 1,00 -
Any All 806/303 0,91 0.76–1.09 298/293 0,93 0.74–1.16
No Women 669/244 1,00 - 236/205 1,00 -
Any Women 568/215 0,96 0.78–1.19 224/206 0,94 0.72–1.23
No Men 281/81 1,00 - 92/94 1,00 -
Any Men 238/88 0,78 0.55–1.10 74/87 0,87 0.57–1.33
Ca/Co=Cases and controls.
OR=odds ratio.
95% CI=95% confidence interval.
doi:10.1371/journal.pone.0017880.t001
Effects of GSTM1 in Rheumatoid Arthritis
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17880incident cases, differences in results may have occurred due to an
influence of GSTM1 variations on disease development and thus
on which cases were available for recruitment in a long-lasting RA
population. Interestingly, the largest previous studies of genetic risk
from GSTM1 (n the Nurese Health Study; Keenan et al (19) was
also based on population-based recruitment and was not sensitive
to selection on long-time severity, and this study on 549 RA cases
and controls, Keenan et al. [20] could not demonstrate any
association between GSTM1 and development of RA. Also a
smaller study on 115 incident cases was not able to identify any
association of CNV [18] with RA.
Previously there was no robust technique to detect difference
between heterozygous and homozygous states for the non-null
GSTM1 genotype. In the current study the effect from 2 copies of
the gene in comparison with null genotype was investigated for the
first time. However, not even using this refined analytic method
provided any association between GSTM1 CNV on risk for RA in
general. However, an increased risk was seen in the subgroup of
non-smoking women $60 years old (though with broader
confidence interval), most likely due to reduced power in our
analyses compared to when analyzing presence ($1 copy) vs.
absence (0 copies) of GSTM1. This gene dosage effect nevertheless
strengthens the possibility that there is a real association between
GSTM1 CNV and risk for RA in this subset of older non-smoking
women.
It was previously suggested by Mattey et al., [17] that deletion of
the GSTM1 gene may influences RA severity measured as Larsen
scores. This study was performed in a group of smokers with RA.
Table 2. Influence of GSTM1 on development of ACPA-positive RA in relation to SE and smoking.
No GSTM1 – ACPA-positive RA
SE Sex Ca/co OR 95% CI
No All 97/204 1.0 -
Any All 571/322 3.73 2.83–4.92
No GSTM1 – ACPA-positive RA
Smoking Sex Ca/co OR 95% CI
Never All 147/212 1.0 -
Ever All 392/325 1.74 1.35–2.25
No/Yes GSTM1 – ACPA-positive RA
SE, Ever smoker, No GSTM1 Sex Ca/co OR 95% CI
No SE, Never smoker, No GSTM1 All 25/97 1.0 -
Yes SE, Ever smoker, No GSTM1 All 338/164 8.0 4.96–12.89
Yes SE, Ever smoker, Yes GSTM1 All 296/154 7.46 4.61–12.06
Ca/Co=Cases and controls.
OR=odds ratio.
95% CI=95% confidence interval.
doi:10.1371/journal.pone.0017880.t002
Table 3. Frequency of GSTM1 CNV and severity of RA.
Covariate Copies Cases Mean
Lower 95%–
Upper 95% p
DAS28 0.82
0 755 4.99 4.90–5.09
1 524 5.06 4.94–5.18
2 107 4.96 4.70–5.22
3 3 4.99 3.43–6-56
Larsen score, female smokers 0.04
0 36 3.54 1.77–5.32
1 28 5.42 3.41–7.43
2 4 7.19 1.86–12.52
3 1 3 7.66–13.66
DAS28 and Larsen score retrieved at baseline.
Non-parametric statistical test (Mann-Whitney).
doi:10.1371/journal.pone.0017880.t003
Table 4. Presence of GSTM1 and risk of developing ACPA-
positive and ACPA-negative RA in relation to gender and age.
GSTM1 – ACPA-negative RA, male smokers
GSTM1 Ca/co OR 95% CI
No 41/97 01.00 -
Any 74/98 00.56 0.35–0.90
GSTM1 – ACPA-positive RA, female $60 years
GSTM1 Ca/co OR 95% CI
No 120/116 1.00 -
Any 122/161 1.37 0.96–1.93
No SE, No GSTM1 17/73 1.00 -
No SE, Yes GSTM1 49/23 2.02 0.98–4.16
Never smokers, No GSTM1 25/71 1.00 -
Never smokers, Yes GSTM1 36/51 2.00 1.07–3.74
Never smokers, No SE, No GSTM1 10/19 1.00 -
Never smokers, No SE, Yes GSTM1 4/36 3.32 0.86–12.77
Ca/Co=Cases and controls.
OR=odds ratio.
95% CI=95% confidence interval.
doi:10.1371/journal.pone.0017880.t004
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population regarding GSTM1 CNV and disease activity at onset of
disease or on rate of joint destruction after 1 or 2 years from
diagnosis. Some trend for an influence of GSTM1 CNV on the
baseline Larsen scores in female smokers was seen, but in opposite
direction to what was has been described previously. We observed
that ever smokers with at least one copy of GSTM1 had more
erosions in comparison to patients without GSTM1. This
difference in relation to previously published data again could be
well due to differences in selection criteria and population
heterogeneity between the British (16) and our study. The
conclusion in this article originated from analysis of 80 non-
smokers and 84 smokers from UK Caucasian population with RA.
In a regression model for this study the GSTM1-null state together
with smoking provided only nominal p-value for regression
coefficient (0.03), while the coefficients related to RF and disease
duration were more robust (0.002 and ,0.0001). This made the
whole regression model for Larsen scores highly significant, but
likely mainly dependent on other contributors than GSTM1.
Finally, a study of 213 RA patients from Slovenia did not identify
any association between variations in GSTM1 and DAS28 levels
at the time of inclusion and these data are thus also in line with our
finding [23].
Criswell et al., [18], who studied 115 incident cases described an
association between GSTM1 null homozygosity and risk for RA in
older Caucasian women. They also observed that cigarette smoking
was a more important risk factor for RA among those who carry the
GSTM1 gene. In order to specifically see whether we could replicate
the results from this study, we excluded subjects below 60 years of
age and thus analyzed female cases with an average age of 64 years
(338 ACPA-positive cases, 166 ACPA-negative cases and 281
controls). We found an increased risk of developing ACPA-positive
RA in non-smoking older females carrying GSTM1 (OR: 2.12 95%
CI: 1.14–3.95) as well as a trend in older females lacking the SE
(OR: 2.02 95% CI: 0.98–4.16), thereby partly confirming some of
the findings from Criswell et al in our larger study population.
In conclusion, our results suggest that GSTM1 presence may
increase risk of developing RA, but this effect is different in
different subgroups of RA and is modified by gender and age. For
future studies, it would be interesting to see if these results would
be replicated in other large Caucasian and non-Caucasian study
populations. Since we found a trend towards an association in
individuals who lack the SE alleles and as SE does not appear to be
an important risk factor for RA among certain non-Caucasian
populations such as African and Hispanic American groups, it
would be particularly interesting to study such groups in relation to
genetic risk from GSTM1 [24,25]. In addition, genetic variation
and epigenetic regulation of other enzymes involved in detoxifi-
cation of products of smoking may be of high interest for
understanding the mechanisms behind development of RA.
Materials and Methods
Ethics statement
96–174 EIRA. The research project IRB no 96–174 was
approved 29/08/96 by the former local institutional review board
at the Karolinska Institute.
Study population
This study was based on a case-control study, the Epidemiolog-
ical Investigation of Rheumatoid Arthritis (EIRA). The material
involves incident cases of RA from different parts of Sweden ((2426
incident cases (1727 females and 699 males) of RA and 1257
controls (897 females and 360 males)). Successful genotyping was
performed for 2386 (98,4%) cases (1700 females and 686 males) and
1249 (99,4%) controls (891 females and 358 males). Within this
material we had access to data on baseline disease activity (DAS28)
in 1426 cases (998 females and 428 males). Distribution of age,
gender and ACPA status is depicted in Table 5. The study was
approved by the ethics committee at the Karolinska Institutet and
by Regional Stockholm ethics committee.
Definition of smoking status
Smokingstatuswasdefinedaccordingtothe EIRA questionnaire,
as described previously [26]. For each case, the year when the first
symptoms of RA occurred was defined as the index-year and the
same index-year was used for the corresponding control. Briefly,
subjects who reported that they regularly smoked cigarettes during
or before the index-year were defined as ever smokers and those who
reported that they had never smoked tobacco before or during the
index-year were defined as never smokers.
ACPA
Detection of antibodies to citrulline-containing peptides was
performed using the Immunoscan-RA Mark2 ELISA test (Euro-
Diagnostica, Malmo ¨, Sweden). A level of .25 units/ml was
interpreted as being positive according to instructions in the kit
and as confirmed by validation at the Clinical Immunology
laboratory at Uppsala University Hospital, Sweden.
Radiographs
Radiographs were scored by an experienced investigator
(MCW) according to the Larsen method [27] as previously
described [28] and documented using the X-Ray RheumaCoach
software [29]. Information on change in Larsen score was
obtained by subtracting the baseline Larsen score from the score
at 1 year or the score at 2 years or by subtracting the Larsen score
at 1 year from the score at 2 years.
HLA analysis
2-digit HLA-DRB1 typing was conducted using sequence-
specific primer polymerase chain reaction (SSP-PCR) (DR low-
resolution kit (2-digit); Olerup SSP, Saltsjo ¨baden, Sweden) and the
PCR products were loaded into 2% agarose gels. An interpretation
table was used to determine the specific genotype according to the
manufacturers’ instructions. HLA-DRB1 SE alleles were defined as
*01 (except *0103), *04 and *10.
qPCR
TaqMan Copy Number Assays (Hs02575461_cn) from Applied
Biosystems was used to measure GSTM1 CNV (qPCR). The
Table 5. Baseline characteristics of case and control study
population.
Controls Cases
Number 1257 2426
Females (%) 71.3 71.2
ACPA-positive (%) 0.8 62
Mean age 6 SD (years) 52.9611.6 51.3612.4
ACPA=anti-citrullinated protein antibody.
19 controls and 391 patients were missing ACPA status.
doi:10.1371/journal.pone.0017880.t005
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in a 10 ul reaction volume using a 384 well plate containing 10 ng
dry DNA, 5 ul TaqManH Universal PCR Master Mix, No UNG,
0.5 ul of the CNV assay solution, 0.5 ul of the reference assay
solution (Applied Biosystems) and 4 ul H20. The qPCR was done
using the following cycling conditions: absolute quantification, 95uC
for 10 min hold and 40 cycles of 95uC for 15 sec and 60uC for
60 sec. Each individual was represented in quadruplicates on each
plate, where at least one sample with known copy number of
GSTM1 was included. A complete description of the work flow can
be downloaded from Applied Biosystems website (https://products.
appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavi-
gate2&catID=606182&tab=Literature); Quick Reference Card,
TaqMan Copy Number Assays. The results were analyzed
using the software CopyCaller v1.0 downloadable from www.
appliedbiosystems.com.
PCR
In addition to qPCR, we utilized generic PCR as a quality
control for detection of GSTM1 CNV in genomic DNA (1 ul
DNA, 30 ng/ul). GSTM1 primers, forward 59-CTG GAT TGT
AGC AGA TCA TGC-39, reverse 59-CTC CTG ATG ATG
ACA GAA GCC-39; housekeeping gene b-globulin primers,
forward 59-CAA CTT CAT CCA CGT TCA CC-39, reverse
59-GAA GAG CCA AGG ACA GGT AC-39 [14]. PCR cycling
conditions 94uC initial denaturation 15 min., 94uC 30 sec, 63uC
30 sec and 72uC 30 sec for 30 cycles, extra elongation 72uC,
5 min. 60 samples with 0 and 1 copies were randomly selected and
used for quality control with 100% match between the TaqMan
CNV assay and the generic PCR.
Statistical analyses
In order to investigate the association between different
exposures and risk of developing RA, odds ratios (OR) together
with 95% confidence intervals (CI) were calculated. Chi-square
test was used for smoking and SE analyses and the non-parametric
Kruskal-Wallis test was used when studying DAS28 and Larsen
score (JMP 8.0.1).
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